🧬 #ScienceSaturday What if making CAR-T cells stronger requires removing not one internal brake, but the right combination of brakes?
A new study from @Yale University, published in @Nature, used #CRISPR screening to look for pairs of genes that, when switched off together, could make CAR-T cells better cancer fighters.
🔬 Instead of testing one gene at a time, researchers screened thousands of gene combinations directly in living tumor models. That allowed them to identify pairs that worked synergistically, meaning the combined effect was greater than what either gene could achieve alone.
One combination stood out: NR4A1 and SOCS3.
CAR-T cells with both genes removed showed stronger mitochondrial activity, improved metabolic fitness and more durable antitumor responses across several preclinical models.
💡 Why does this matter? CAR-T cells can lose function over time, especially in the difficult environment created by solid tumors. This study suggests that improving CAR-T therapy may require targeting multiple internal pathways at once, rather than looking for a single “best” gene to change.
It also gives researchers a new way to systematically search for those combinations, which could help guide the design of next-generation cell therapies.
There’s still more work to do before these findings translate to patients, but the study highlights an important idea: sometimes, the key to a stronger T cell may be finding the right combination of brakes to release. @sidichen@MuschenLab@Yale@YaleMed@YaleCancer@YaleGenetics@YaleWestCampus@YaleIBIO@TheWistar@PennMedicine@BCMHouston@BCMCancerCenter@CancerResearch@ACGTFoundation@psscra@PCFnews@PCF_Science@NatureComms@NaturePortfolio
📄 Read the study: nature.com/articles/s41586-0…
Every gift to cancer research has a story. 💜
This #NationalPhilanthropyDay, meet two CRI donors: Arthur, a 30-year survivor giving in honor of family lost to cancer, and Rob, giving in memory of Vicky.
Add your story: bit.ly/3UVxFAi#Immune2Cancer
Thank you to our partners and community for making possible these investments in innovative investigators and research poised to break barriers! 🧡
Read more about the 2026 KCA Research Awards in our press release - kidneycancer.org/2026-grant-…
What drove the rapid growth of combination therapy trials, and why has that growth slowed?
The research examines the scientific, regulatory, and commercial factors shaping the development of cancer immunotherapy. (2/3)
A new @NatRevDrugDisc analysis of 12,160 immune checkpoint inhibitor clinical trials revealed a striking gap: 84% investigated combination therapies, yet these accounted for just 48% of related FDA approvals between 2011 and 2025. (1/3) #CancerImmunotherapy
A stage 4 lung cancer diagnosis changed retired Navy Commander John Ryan’s life. An immunotherapy clinical trial helped save his life.
This #VeteransDay, discover his story and how CRI-funded research is advancing cancer treatment for veterans: bit.ly/4itB4hI
From NK cell therapies to AI, #SITC26 explored the future of #cancerimmunotherapy.
Our recap highlights @EricVivier1's Coley Award Lecture, a discussion with CRI STAR Yvonne Chen & new research on checkpoint bispecific antibodies.
Missed it? bit.ly/3WtBPjr@sitcancer
Leaving #SITC26 with new research ideas? 💡
Several CRI grants, ranging from $300K to $1M, have deadlines coming up, starting Nov. 15.
Explore funding opportunities and apply: bit.ly/4sL8oFG#CancerImmunotherapy@sitcancer
Today at #SITC26, 2026 Coley Award recipient Éric Vivier, DVM, PhD, delivers a lecture on the role of NK cells in cancer therapy! 🌟
📅 9:55 AM MST | Hall A
Learn more: bit.ly/4BHtOYk@sitcancer@EricVivier1
More CRI-funded research at #SITC26!
Today at 1:45 PM MST, CRI STARs lead a session on combinations involving cell therapies.
• Yvonne Chen, PhD, @UCLA
• Anusha Kalbasi, MD, @StanfordMed
• Mohammad Rashidian, PhD, @DanaFarber
View schedule: bit.ly/3UmhtYJ
✨ From the CRI Gala to #SITC26! Honored at our October Gala, Éric Vivier, DVM, PhD, will deliver the CRI William B. Coley Award Lecture in just 2 days!
🔬 Nov 8 | 9:55 AM MST
📍 Phoenix Convention Center
Explore the science: bit.ly/3UmhtYJ@sitcancer
CRI STARs take the stage at #SITC26 today!
🔹 @j_eyquem (@UCSF): In vivo and Solid Tumor CAR-T Cell Therapies | 3:10 PM
🔹 @gmdelgoffe (@PittTweet): Funding Your Research Through Industry Collaboration | 3:15 PM
Explore the sessions: bit.ly/3UmhtYJ
#SITC26 kicks off today in Phoenix! CRI-funded scientists, including seven CRI STARs, are sharing their latest research. Plus, Éric Vivier delivers the inaugural CRI Coley Award Lecture at SITC on Sunday.
Explore the sessions: bit.ly/3UmhtYJ@sitcancer